Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GreeceBack to Greece

Clinical trials in Patras – page 19

260 clinical trials in Patras, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Patras at a glance
260
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

260 trials in Patras

Open in trial search

Plasma cell myeloma

Not recruiting

Study Comparing Daratumumab with Drug Combination for Young Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Ceska Myelomova Skupina z.s.

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

IgA nephropathy

Not recruiting

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

HER2 positive breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Short stature+3

Not recruiting

Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Sickle cell disease

Not recruiting

Study on the Effects of Etavopivat for Patients Aged 12-65 with Sickle Cell Disease

Investigational
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etavopivat
  • Sponsor:Novo Nordisk A/S

Plasma cell myeloma

Not recruiting

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Celgene Corp.

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Myelodysplastic syndrome

Not recruiting

Study Comparing Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low-Risk Myelodysplastic Syndrome Who Are Not Dependent on Blood Transfusions

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Celgene Corp.

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of RO7434656 for Patients with Primary IgA Nephropathy at High Risk of Progression

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 696844
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Greece

The busiest research cities in the country

All 50 cities in Greece

Clinical research in Patras

What the registry says about research in the country

01 Autoimmune Conditions

Innovative research focusing on Sjögren's Syndrome and Systemic Sclerosis, evaluating novel therapeutic approaches with medications like sibeprenlimab and efgartigimod. These trials aim to improve treatment outcomes for patients with chronic autoimmune disorders.

  • Sjögren's Disease Management
  • Systemic Sclerosis Treatment
  • Inflammatory Disease Therapy

Studies are exploring both long-term safety and immediate efficacy of new treatment options.

02 Oncology Research

Comprehensive studies in Multiple Myeloma and advanced cancers, including trials of combination therapies and novel treatments. Research includes investigations into treatments for newly diagnosed and relapsed/refractory cases.

  • Multiple Myeloma Therapies
  • Lung Cancer Treatment
  • Prostate Cancer Management

Focus on improving patient outcomes through targeted and combination therapies.

03 Neurological Disorders

Groundbreaking research in Amyotrophic Lateral Sclerosis and Myasthenia Gravis, evaluating innovative treatments and therapeutic approaches for these challenging neurological conditions.

  • ALS Treatment Development
  • Neurological Disease Management
  • Chronic Neurological Conditions

Studies are examining both disease progression and symptom management.

Back to GreeceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.